CHEMOTHERAPY OF HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS - CURRENT PRACTICE AND FUTURE-PROSPECTS

被引:45
作者
HIRSCH, MS
机构
[1] Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
关键词
D O I
10.1093/infdis/161.5.845
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
As human immunodeficiency virus type 1 (HIV-l) has become better understood, numerous drugs have been developed that act at virus-specific sites. These are challenging our ability to evaluate them thoroughly and rapidly. Zidovudine (AZT) remains the mainstay of anti-HIV-l drugs. Recent controlled trials indicate it should be used early in infection (in those with CD4 cell counts <500/mm3) and in lower doses (500-600 mg/day). Prolonged AZT treatment in patients with AIDS, however, is often associated with viral resistance.Newer reverse transcriptase inhibiting nucleoside derivatives are currently in phase IT-III clinical trials.Other HIV-l replicative sites under attack in clinical studies include binding and entry of virus, envelope protein g1ycosylation, and viral assembly and release.Agents that target HIV-l proteinase, Integrase, ribonuclease H, and products of regulatory genes such as tat are under development. Combination therapies that target different viral replicative sites likely will allow use of individual agents below their toxic concentrations and help prevent drug resistance. Innovative programs for expanded access to experimental drugs are needed that will permit expeditious clinical trials, optimize the gathering of useful information, and permit the widest access to promising treatments. © 1990 by the University of Chicago. All rights reserved.
引用
收藏
页码:845 / 857
页数:13
相关论文
共 85 条
[1]   OLIGODEOXYNUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHOROTHIOATES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS [J].
AGRAWAL, S ;
GOODCHILD, J ;
CIVEIRA, MP ;
THORNTON, AH ;
SARIN, PS ;
ZAMECNIK, PC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) :7079-7083
[2]  
BALZARINI J, 1987, MOL PHARMACOL, V32, P162
[3]  
BERMAN E, 1989, BLOOD, V74, P1281
[4]   RETROVIRAL INTEGRATION - STRUCTURE OF THE INITIAL COVALENT PRODUCT AND ITS PRECURSOR, AND A ROLE FOR THE VIRAL IN PROTEIN [J].
BROWN, PO ;
BOWERMAN, B ;
VARMUS, HE ;
BISHOP, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (08) :2525-2529
[5]   DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[6]   SELECTIVE KILLING OF HIV-INFECTED CELLS BY RECOMBINANT HUMAN CD4-PSEUDOMONAS EXOTOXIN HYBRID PROTEIN [J].
CHAUDHARY, VK ;
MIZUKAMI, T ;
FUERST, TR ;
FITZGERALD, DJ ;
MOSS, B ;
PASTAN, I ;
BERGER, EA .
NATURE, 1988, 335 (6188) :369-372
[7]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[8]   SOLUBLE CD4 BLOCKS THE INFECTIVITY OF DIVERSE STRAINS OF HIV AND SIV FOR T-CELLS AND MONOCYTES BUT NOT FOR BRAIN AND MUSCLE-CELLS [J].
CLAPHAM, PR ;
WEBER, JN ;
WHITBY, D ;
MCINTOSH, K ;
DALGLEISH, AG ;
MADDON, PJ ;
DEEN, KC ;
SWEET, RW ;
WEISS, RA .
NATURE, 1989, 337 (6205) :368-370
[9]   SURVIVAL EXPERIENCE AMONG PATIENTS WITH AIDS RECEIVING ZIDOVUDINE - FOLLOW-UP OF PATIENTS IN A COMPASSIONATE PLEA PROGRAM [J].
CREAGHKIRK, T ;
DOI, P ;
ANDREWS, E ;
NUSINOFFLEHRMAN, S ;
TILSON, H ;
HOTH, D ;
BARRY, DW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (20) :3009-3015
[10]  
DERAY G, 1988, NEW ENGL J MED, V319, P1606, DOI 10.1056/NEJM198812153192412